GD2-CAR T-cells

GD2-CAR T-cells are an autologous cell therapy consisting of T-cells engineered to express a chimeric antigen receptor (CAR) targeting the disialoganglioside GD2. GD2 is a surface glycolipid highly expressed in various neuroectoderm-derived tumors, including neuroblastoma and H3K27M-mutated diffuse midline gliomas (DMG). The therapy involves harvesting a patient's T-cells, modifying them ex vivo to recognize GD2, and re-infusing them into the patient. In clinical trials for DMG, such as those led by Stanford University (NCT04196413), the cells are administered via intravenous and intracerebroventricular routes to maximize tumor exposure within the central nervous system. The treatment aims to induce a robust immune response against tumor cells while managing potential toxicities like neuroinflammation and immune rejection mediated by humanized anti-CAR antibodies (HACA).

Other names

GD2-targeting chimeric antigen receptor T-cellsGD-2-targeting chimeric antigen receptor T-cellsGD 2-targeting chimeric antigen receptor T-cellsanti-GD2 CAR T-cellsanti-GD-2 CAR T-cellsanti-GD 2 CAR T-cells